GlassScriptPhysician profile
Hemant N Shah
NPI 1295743508
$1,353.81
in general payments reported to CMS, 2019-2025
12 companies · $139 in 2025
The $139 reported for 2025 was more than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $349 · 2021: $544 · 2022: $17.23 · 2023: $42.77 · 2024: $55.87 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $400.12 | 2019-2021 | |
| Glaxosmithkline, LLC. | $375.31 | 2019-2022 | |
| Pfizer INC. | $125.44 | 2019-2023 | |
| Genzyme Corporation | $106.79 | 2024-2025 | |
| Amgen INC. | $88.11 | 2020-2021 | |
| Abiomed | $60.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $51.58 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $45.11 | 2025 | |
| Novartis Pharmaceuticals Corporation | $37.97 | 2019 | |
| Collegium Pharmaceutical, INC. | $22.83 | 2025 | Belbuca |
| Novo Nordisk INC | $20.42 | 2020 | |
| Exact Sciences Corporation | $20.13 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemant Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.